Abstract: Provided is a cell suspension culturing apparatus suitable for large-scale culture of cells, the cell culturing apparatus comprising a culture solution aspirator having a double-tube structure comprising an outer tube and an inner tube inserted in a lumen of the outer tube, and a suspension culture vessel, wherein in the culture solution aspirator, the outer tube comprises a filter through which a culture solution is passed, the inner tube comprises a suction port for the culture solution passed through the filter, and an air hole which communicates the lumen of the outer tube with the outside is disposed distally in a direction of insertion of the outer tube into the suspension culture vessel.
Type:
Application
Filed:
December 21, 2018
Publication date:
December 17, 2020
Applicants:
Kyoto University, Takeda Phamaceutical Company Limited
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. (I) wherein each symbol is as described in the specification, or a salt thereof.
Abstract: Disclosed are compounds of the following formula: in which R1, R2, R5, R6, R7, R31, u, and X are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.
Type:
Grant
Filed:
August 1, 2014
Date of Patent:
November 17, 2015
Assignee:
Takeda Phamaceutical Company Limited
Inventors:
Anthony R. Gangloff, Andrew John Jennings, Benjamin Jones, Andre A. Kiryanov
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
Type:
Application
Filed:
May 2, 2013
Publication date:
September 19, 2013
Applicant:
Takeda Phamaceutical Company Limited
Inventors:
Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Christopher Smith, Massashi Takahashi, Qing Dong, Victoria Feher, Zhi Nie
Abstract: The present invention provides a compound represented by the following formula (1); wherein R1 is an aryl group etc.; R2 is —CO—NH— etc.; R3 is a methyl group having an aromatic group or a cycloalkyl group; R4 is a hydrogen atom etc.; R5 is a methyl group having an aromatic group; and R6 is an amino group or an N-alkyl substituted amino group, having a low-molecular weight and a superior GPR54 agonist activity, and a pharmaceutical composition containing the compound.
Type:
Grant
Filed:
October 24, 2006
Date of Patent:
May 22, 2012
Assignees:
Kyoto University, Takeda Phamaceutical Company Limited
Abstract: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanism, the compounds of the invention appear to function at least in part by inhibiting G2 cell cycle checkpoint. Thus, invention compounds can be used to inhibit cell growth alone or be used in combination with a nucleic acid damaging treatment to inhibit cell growth.